PVI
NVCR icon

Pura Vida Investments’s NovoCure NVCR Stock Holding History

Pura Vida Investments’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-265,100
Closed -$19.4M – 139
2022
Q4 		$19.4M Buy
265,100
+120,000
+83% +$9.03M 1% 25
2022
Q3 		$11M Buy
145,100
+55,100
+61% +$4.3M 0.64% 47
2022
Q2 		$6.25M Buy
90,000
+27,300
+44% +$2.06M 0.36% 74
2022
Q1 		$5.2M Sell
62,700
-31,100
-33% -$2.29M 0.17% 120
2021
Q4 		$7.04M Buy
93,800
+29,700
+46% +$2.98M 0.26% 96
2021
Q3 		$7.45M Buy
64,100
+29,400
+85% +$4.45M 0.23% 120
2021
Q2 		$7.7M Buy
+34,700
New +$6.75M 0.24% 90

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Pura Vida Investments's NVCR Position: Q1 2023 in Review

Pura Vida Investments sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 50,000 shares — an estimated $3.67M sold.

Pura Vida Investments first reported a position in NVCR in Q4 2022 and held it in 1 quarter. The position peaked at $3.67M in Q4 2022. 296 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

  • Pura Vida Investments reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 50,000 NovoCure shares in Q1 2023, an estimated $3.67M.
  • Pura Vida Investments first reported a position in NovoCure in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's NovoCure position peaked at $3.67M in Q4 2022.
  • 296 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.